Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 04 Jan 2022 for Ampio Pharmaceuticals, Inc., €34k.
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Michael Macaluso: trading record in brief
Michael Macaluso (chief executive) discloses dealings in 2 companies, chiefly Aytu Biopharma, Inc and Ampio Pharmaceuticals, Inc. In total, 7 filings cover trades dated from 7 July 2016 to 1 January 2022.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The newest entry dates from 4 January 2022: a share grant of €34k, in Ampio Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Michael Macaluso
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
68,400 shares@ US$0.5735.9% of flowCommon StockSEC:0001415889-22-000257:0
43,470 shares@ US$1.6464.1% of flowCommon StockSEC:0001415889-21-005016:0
950,000 shares0Common StockSEC:0001415889-21-004870:0
3 of 3 declarations
